세계의 드라베 증후군(DS) 시장 : 출시 약품과 파이프라인 약품 평가, 임상시험, 경쟁 구도
Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
상품코드
:
1376903
리서치사
:
GlobalData
발행일
:
2023년 10월
페이지 정보
:
영문 70 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
개요
GlobalData DS의 역학 예측에서는 대상 16개국에서 2023년에 12만 3,000을 넘는 DS 환자가 진단될 것으로 예측하고 있습니다.
출시 DS 치료제의 작용기서는 대부분이 수용체 작용제이며, 이온채널 차단제, 수용체 길항제, 효소 저해제가 그 뒤를 잇고 있습니다.
DS 파이프라인은 모든 개발 단계(Drug Discovery로부터 임상 개발 후기까지)에 걸쳐 40 품목으로 구성되어 있으나, 임상 개발 단계에 있는 파이프라인은 전체의 40%에 불과합니다.
과거 10년간 DS에서 개시된 68 임상시험 중 39 시험이 완료했으며, 19 시험이 현재 진행중입니다.
파트너십은 전 세계의 DS 분야에서 가장 현저하게 시행된 거래의 유형이었습니다.
세계의 드라베 증후군(DS) 시장에 대해 조사분석했으며, 질환의 상황, 출시 약품과 파이프라인 약품의 평가, 현재와 향후 경쟁 구도 등을 제공하고 있습니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질환 상황
제4장 출시 약품 평가
- 주요 출시 약품
- 개요 : 작용기서별
- 개요 : 투여 경로별
- 출시 약품 개요와 판매의 예측
제5장 가격결정과 상환 평가
제6장 파이프라인 약품 평가
- 단계 3 파이프라인 약품
- 개요 : 개발 단계별
- 개요 : 분자 유형별
- 개요 : 작용기서별
- 개요 : 투여 경로별
- 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
- 치료 영역과 적응증 고유 PTSR과 LoA
제7장 임상시험 평가
- 과거의 개요
- 개요 : 단계별
- 개요 : 현황별
- 개요 : 진행중/계획 시험 단계별
- 가상 컴포넌트를 사용한 시험
- 지역적 개요
- 단일국·다국간 시험 : 지역별
- 상위 20 스폰서와 내역 : 단계별
- 상위 20 스폰서와 내역 : 현황별
- 개요 : 엔드포인트 현황별
- 개요 : 인종/민족별
- 등록 데이터
- 시험 시설 상위 20개국
- 세계의 상위 20 시설
- 실현 가능성 분석 - 지역적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
- 합병, 인수, 전략적 제휴 : 지역별
- 최근 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후 시장 촉매
제11장 부록
KSA
영문 목차
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in DS therapeutics.
More than 123,000 diagnosed prevalent cases of DS are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for DS.
Most of the marketed drugs for DS are receptor agonists by mechanism of action, followed by ion channel blockers, receptor antagonists, and enzyme inhibitors.
The DS pipeline consists 40 drugs spanning all stages of development (discovery to late-stage clinical development), with only 40% of pipeline drugs present in clinical development.
Of 68 clinical trials initiated in DS over the past 10 years, 39 trials have been completed while 19 trials are currently ongoing.
Partnerships were the most prominent type of deal ventured in the DS space globally.
Scope
GlobalData's DS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
관련자료
